A Phase I/II, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogenic Anti-CD7 Car-T Cells BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia T-ALL or T-Cell Lymphoblastic Lymphoma T-LL

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT05885464

Study #:
STUDY00150327

Start Date:
Oct 26, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05885464

View Complete Trial Details & Eligibility at ClinicalTrials.gov